Alternating circumferential bridge stent design and methods for use thereof

Information

  • Patent Grant
  • 10092427
  • Patent Number
    10,092,427
  • Date Filed
    Thursday, November 4, 2010
    14 years ago
  • Date Issued
    Tuesday, October 9, 2018
    6 years ago
Abstract
A stent includes a first section and a second section. The first section and the second section each include a plurality of expandable modules and a plurality of bridging modules. Each expandable module includes a plurality of strut elements that join together at a plurality of apices, and each bridging module includes bridging elements that connect an apex of a first module with an apex of a second module. In some aspects, the first section is more flexible along the longitudinal axis of the stent than the second section and is configured to be placed in a specific region of a vessel that requires flexibility to accommodate surrounding anatomy. In some aspects, the first section is more radially stiff than the second section and is configured to be placed in a specific region of the vessel that requires radial stiffness to counteract crushing force caused by surrounding anatomy.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


FIELD OF THE INVENTION

The present invention relates to stents and more particularly to stents having different modules that when combined provide advantages for the physiological challenges posed in particular anatomies.


BACKGROUND OF THE INVENTION

Generally, stents are used as an alternative to surgery to obtain and maintain the patency of a variety of body passageways, while maintaining the integrity of the passageway. The environments of human vasculature and body passageways are characterized by varied, dynamic, and mobile anatomy. Vessels vary from simple to complex shapes, can be uniform in diameter or change abruptly or gradually from one diameter to another, and are subjected to a range of forces exerted by an assortment of anatomical structures surrounding and adjacent to these body passageways. It is critical that stents be designed to accommodate significant variation in the shape and size of body passageways while providing structural support and flexibility as required by particular indications of use.


The primary role of a stent is to provide radial expansion and scaffolding within the affected segment, thereby improving flow and preserving the viability and full function of distal tissues. In performing this primary function, however, a stent must exist in harmony with surrounding structures of the body, including vessels, nerves, muscles, organs, and other tissues. Each region of the anatomy presents a unique combination of loads, interactions, and constraints that will be experienced by the implant. In many regions of the anatomy, these boundary conditions will vary not only with location, but also with time. These temporal variations, including motions associated with the cardiac pulsatile cycle, gait cycle, respiratory cycle, or other dynamic events, are especially important considerations for the durability of the implant itself, as well as the efficacy of the therapy. Consequently, stent designs are needed that can (1) provide adequate outward radial support to remodel the lumen and improve distal perfusion, (2) provide adequate crush recoverability when subjected to compression by the surrounding muscles or external forces, (3) provide adequate flexibility to accommodate localized stretching, compression, bending, or torsion in mobile segments of the artery, (4) provide durability to survive the cyclic motions associated with limb flexion, and (5) provide uniform scaffolding throughout the treatment region, including the local regions adjacent to calcification that may be subjected to highly focal cyclic loading or displacement. These competing demands have proven difficult to resolve with a single design.


SUMMARY OF THE INVENTION

In general, in one aspect, a stent includes a first section and a second section aligned with the first section along a longitudinal axis of the stent. The first section and the second section each include a plurality of expandable modules and a plurality of bridging modules. Each expandable module includes a plurality of strut elements that join together at a plurality of apices. Each bridging module includes bridging elements that connect an apex of a first module with an apex of a second module. The first section is more flexible along the longitudinal axis than the second section and is configured to be placed in a specific region of a vessel that requires flexibility to accommodate surrounding anatomy.


This and other embodiments can include one or more of the following features. The second section can be configured to provide more radial stiffness than the first section and can be configured to be placed in a specific region of the vessel that requires radial stiffness to counteract crushing force caused by surrounding anatomy.


The plurality of bridging modules can be arranged to alternate along the longitudinal axis between clockwise bridging modules and counterclockwise bridging modules the clockwise bridging modules including bridging elements that extend at a clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a counterclockwise angle with respect to the longitudinal axis. The clockwise bridging modules can be configured to counterbalance any rotation caused by the counterclockwise bridging modules.


There can be a greater number of bridging elements around a circumference of the first section than a circumference of the second section. A length of each bridging element of the first section can be greater than a length of each bridging element of the second section. A pitch of the bridging elements within each bridging module of the first section can be greater than a pitch of the bridging elements within each bridging module of the second section. A width of each bridging element of the first section can be less than a width of each bridging element of the second section. A thickness of each bridging elements of the first section can be less than a thickness of each bridging element of the second section.


There can be a greater number of strut elements around a circumference of the first section than a circumference of the second section. A length of each strut element of the first section can be less than a length of each strut element of the second section. A width of each strut element of the first section can be less than a width of each strut element of the second section. A thickness of each strut element of the first section can be less than a thickness of each strut element of the second section.


The vessel can be a left iliac vein, and the specific region can be proximate to where a left common iliac vein crosses an inguinal ligament. The vessel can be a superficial femoral artery, and the specific region can be between a profunda and an adductor hiatus. The vessel can be a coronary artery, and wherein the specific region can be near a branch vessel. The vessel can be a renal artery, and the specific region can be near an ostium. The vessel can be a carotid artery, and the specific region can be near a carotid sinus. The vessel can further be a trachea, a fistula, or a graft.


In general, in one aspect, a method of inserting a stent includes inserting a stent into a vessel. The stent includes a first section and a second section. The first section is more flexible along a longitudinal axis of the stent than the second section. The first section and the second section each include a plurality of expandable modules and a plurality of bridging modules. Each expandable module includes a plurality of strut elements that join together at a plurality of apices. Each bridging module includes bridging elements that connect an apex of a first module with an apex of a second module. The method further includes aligning the first section with a specific region of the vessel that requires flexibility to accommodate surrounding anatomy.


This and other embodiments can include one or more of the following features. The second section can be configured to provide more radial stiffness than the first section, and the method can further include aligning the second section with a specific region of the vessel that requires radial stiffness to counteract crushing force caused by surrounding anatomy.


The plurality of bridging modules can be arranged to alternate along the longitudinal axis between clockwise bridging modules and counterclockwise bridging modules, the clockwise bridging modules including bridging elements that extend at a clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a counterclockwise angle with respect to the longitudinal axis.


The vessel can be a left iliac vein, and the specific region can be proximate to where a left common iliac vein crosses an inguinal ligament. The vessel can be a superficial femoral artery, and the specific region can be between a profunda and an adductor hiatus. The vessel can be a coronary artery, and the specific region can be near a branch vessel. The vessel can be a renal artery, and the specific region can be near an ostium. The vessel can be a carotid artery, and the specific region can be near a carotid sinus. The vessel can further be a trachea, a fistula, or a graft.


In general, in one aspect, a stent includes a first section and a second section aligned with the first stent section along a longitudinal axis of the stent. The first section and the second section each include a plurality of expandable modules and a plurality of bridging modules. Each expandable module includes a plurality of strut elements that join together at a plurality of apices. Each bridging module includes bridging elements that connect an apex of a first module with an apex of a second module. The first section is more radially stiff than the second section and is configured to be placed in a specific region of the vessel that requires radial stiffness to counteract crushing force caused by surrounding anatomy.


This and other embodiments can include one or more of the following features. The second section can be more flexible along the longitudinal axis than the first section and can be configured to be placed in a specific region of a vessel that requires flexibility to accommodate surrounding anatomy.


The plurality of bridging modules can be arranged to alternate along the longitudinal axis between clockwise bridging modules and counterclockwise bridging modules, the clockwise bridging modules including bridging elements that extend at a clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a counterclockwise angle with respect to the longitudinal axis. The clockwise bridging modules can be configured to counterbalance any rotation caused by the counterclockwise bridging modules.


There can be a smaller number of bridging elements around a circumference of the first section than a circumference of the second section. A length of each bridging element of the first section can be greater than a length of each bridging element of the second section. A pitch of the bridging elements within each bridging module of the first section can be greater than a pitch of the bridging elements within each bridging module of the second section. A width of each bridging element of the first section cam be greater than a width of each bridging element of the second section. A thickness of each bridging element of the first section can be greater than a thickness of each bridging element of the second section.


There can be a smaller number of strut elements around a circumference of the first section than a circumference of the second section. A length of each strut element of the first section can be less than a length of each strut element of the second section. A width of each strut element of the first section can be greater than a width of each strut element of the second section. A thickness of each strut element of the first section can be greater than a thickness of each strut element of the second section.


The vessel can be a left iliac vein, and the specific region can be proximate to where a right iliac artery crosses a left common iliac vein. The vessel can be a left iliac vein, and the specific region is proximate to where a left internal iliac artery crosses a left common iliac vein. The vessel can be a superficial femoral artery, and the specific region can be proximate to an inguinal ligament. The vessel can be the superficial femoral artery, and the specific region can be proximate to a Hunters canal. The vessel can be a coronary artery, and the specific region can be distant from a branch vessel. The vessel can be a renal artery, and the specific region can be distant form an ostium. The vessel can be a carotid artery, and the specific region can be distant from a sinus. The vessel can further be a trachea, a fistula, or a graft.


In general, in one aspect, a method of inserting a stent includes inserting a stent into a vessel. The stent includes a first section and a second section. The first section is more radially stiff than the second section. The first section and the second section each include a plurality of expandable modules and a plurality of bridging modules. Each expandable module includes a plurality of strut elements that join together at a plurality of apices. Each bridging module includes bridging elements that connect an apex of a first module with an apex of a second module. The method further includes aligning the first section with a specific region of the vessel that requires radial stiffness to counteract crushing force caused by surrounding anatomy.


The second section can be more axially flexible than the first section, the method further comprising aligning the second section with a specific region of the vessel that requires flexibility to accommodate surrounding anatomy.


The plurality of bridging modules can be arranged to alternate along the longitudinal axis between clockwise bridging modules and counterclockwise bridging modules, the clockwise bridging modules including bridging elements that extend at a clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a counterclockwise angle with respect to the longitudinal axis.


The vessel can be a left iliac vein, and the specific region can be proximate to where a right iliac artery crosses a left common iliac vein. The vessel can be a left iliac vein, and the specific region is proximate to where a left internal iliac artery crosses a left common iliac vein. The vessel can be a superficial femoral artery, and the specific region can be proximate to an inguinal ligament. The vessel can be the superficial femoral artery, and the specific region can be proximate to a Hunters canal. The vessel can be a coronary artery, and the specific region can be distant from a branch vessel. The vessel can be a renal artery, and the specific region can be distant form an ostium. The vessel can be a carotid artery, and the specific region can be distant from a sinus. The vessel can further be a trachea, a fistula, or a graft.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which.



FIG. 1 shows an exemplary stent as described herein.



FIG. 2 is a close up of a portion of an expandable ring member described herein.



FIGS. 3A-3B are depictions of the relationship of the stent to vessel and lesion diameters.



FIG. 4 is a close up of a portion of a bridging member described herein.



FIG. 5 shows a stent as described herein bent axially.



FIG. 6A shows a stent having bridge elements arranged axially.



FIG. 6B shows a stent having bridge elements arranged circumferentially.



FIG. 6C shows a chart of variables vs. module characteristics for the stents described herein.



FIG. 7A is an illustration of the anatomy of the venous system within the pelvic region.



FIG. 7B is an illustration showing the spatial relationship of the anatomy of the right common iliac artery and the left common iliac vein whereby portions of the left common iliac vein are pinched by the right common iliac artery.



FIG. 7C is an illustration demonstrating the compression of the left common iliac vein between the spine and the right common iliac artery.



FIG. 8 shows an exemplary stent for treatment of IVCS.



FIGS. 9A-9C show the femoral arteries and surrounding anatomy.



FIG. 10 shows an exemplary stent for a femoral artery.



FIG. 11 shows the coronary arteries.



FIGS. 12A-12B show an exemplary stent for a coronary artery.



FIG. 13 shows the renal arteries.



FIG. 14 shows an exemplary stent for a renal artery.



FIG. 15 shows the carotid arteries.



FIG. 16 shows an exemplary stent for a carotid artery.



FIGS. 17A-B show hemodialysis access grafts and fistulae.



FIGS. 18A-18B show the trachea and bronchi.



FIGS. 19A-19B show the response of the trachea during coughing.





DETAILED DESCRIPTION OF THE INVENTION

Embodiments of the present invention are directed toward stents having a modular architecture that permits regions of the stent to be specifically tailored to the specific anatomical challenges of the vessel undergoing treatment. While applicable to other portions of the body where compression resistive and/or flexible stents are well suited, the illustrative embodiments described herein are directed at stents designed to resolve obstructive lesions of the pelvic veins, femoral arteries, coronary arteries, renal arteries, carotid arteries, fistulae, and the trachea.


Embodiments of the stent described herein include a combination of a number of different modules. The physical and engineering properties of each module are tailored depending upon the required function of the module with respect to the rest of the stent. Examples of different types of modules include: (1) modules designed to provide radial stiffness to anchor the stent or to resist external compressive forces; and (2) modules configured to provide added flexibility to the stent within the treated vessel in order to maintain patency of the vessel. Stent embodiments according to the present invention include one or more modules that are specifically sized and positioned with respect to one another so as to conform to a specific anatomical position.


Stent Description


Referring to FIG. 1, a stent 100 can include a series of expandable ring members 102 connected by bridging members 104. Each expandable ring member 102 can include a series of strut elements 120 disposed around the circumference of the stent 100. Moreover, each bridging member 104 can include circumferential bridging elements 140 connecting the struts 120 of adjacent expandable ring members 102. The pitch of the circumferential bridging elements 140 can alternate between bridging members 104. The number, design, order, and connection of the expandable ring members 102 and bridging members 104 define the overall architecture of the stent 100. The strength, stiffness, flexibility, and inner rotation of the stent can be controlled by the selection and design of these expandable ring members 102 and bridging members 104.


Expandable Ring Members


Referring to FIGS. 1 and 2, the expandable ring members 102 can include a series of struts 120 arranged in a zig-zag shape around the circumference of the stent 100. That is, the struts 120, arranged around the circumference of the stent 100, can connect together at apices 122.


Radial Stiffness


The zig-zag shape of the expandable members 102 can be designed to provide a specific radial stiffness. Such radial stiffness can be important for resisting concentric or eccentric radial forces and maintaining the shape of the stent 100 once deployed.


The stiffness, k, of a ring member 102 when subjected to a hoop load, e.g., as a result of a perfectly concentric lesion, can be approximated by the following relationship:

khoop∝(Ew3t)/(nL3)  [1]

where each expandable ring member 102 include a series of n struts 120 disposed around the circumference of the stent 100, each strut having a length L, a width w, a thickness t, and made of a material having a Young's Modulus E. In this mode of loading, the “hoop” stiffness is dominated by the cube of the strut width, and inversely related to the cube of the strut length.


Moreover, the stiffness, k, of a ring member 102 when subject to a pinching or buckling load, e.g., as a result of eccentric loads, can be described by a different stiffness formulation:

kpinching∝(Ewt3)/(nL3)  [2]

In this mode of loading, “pinching” stiffness is dominated by the cube of wall thickness, rather than strut width as it was for hoop stiffness. An effective stent for treatment of a vessel subject to pinching or buckling, therefore, will maximize wall thickness to maximize resistance to the pinching load experienced.


The zig-zag shape of the expandable members 102, in combination with the radial stiffness, can be further designed to provide a specific restorative force, acting in a radially outward direction to restore the patency of the a constricted lumen. Having a high restorative force can be important for providing the initial expansion force and for resisting concentric or eccentric radial forces placed on the stent 100 after implantation.


Referring to FIGS. 3A-3B, to increase the force applied, the diameter Ds of each expandable member can be chosen to be somewhat larger than the largest effective diameter Dv of the reference vessel. Referring to FIG. 3A, for areas having concentric lesions, the expandable member can be designed to have a uniform expansion force. As such, Ds−Dv>0, and the inserted expandable member can remain in contact with the vessel at all times and all locations. In contrast, referring to FIG. 3B, for areas having eccentric lesions, such as in areas where compression, luminal webbing, or spurs further constrict the effective lumen diameter to Dc, the expandable member 7 can be designed to provide additional force at a particular location. Accordingly, the inserted expandable member will be more constrained (or “oversized”) in this area of constriction than in the area of normal lumen: (Ds−Dc)>(Ds−Dv).


The amount of restorative force generated by a strut deflected by a distance δ can be expressed by the following equation for hoop force:

Fhoop=[(12*E*I)/(L3)]*δ

where E is Young's Modulus for the material, I is the moment of inertia of the strut with respect to its axis of bending as the stent expands or contracts, L is the length of the strut, and δ is the magnitude of strut deflection. Thus, the amount of force that a particular module can apply is enhanced by maximizing the number of struts around the circumference


Axial Flexibility


It is commonly desirable to provide a stent structure that allows for smooth contouring and apposition in curved vessels or lumens following an irregular axial path. In such cases, the ideal stent can vary its local curvature in a continuous manner to accommodate any state of vessel bending. To maximize axial flexibility, it is desirable to decrease the axial length of strut elements 120, as bending is more likely to occur at the transition between the adjacent expandable members 102. Generally, axial flexibility of the stent is improved by minimizing the width w and thickness t of these strut elements 120, as this decreases the overall stiffness of the structure. Similarly, as the number of struts 120 around the circumference increases, strut width typically decreases, as there is a finite amount of material from which to form the struts, which also tends to improve axial flexibility.


Bridging Members


Referring back to FIG. 1, adjacent bridging members 104 can have bridging elements 140 that extend between apices 122 of adjacent expandable members 102. The bridging elements 140 can extend in a circumferential direction, i.e. between 0° and 90° from the longitudinal axis 110 of the stent.


As shown in FIG. 1, the bridging elements 140 of adjacent bridging members 104 along the longitudinal axis 106 of the stent can have an opposite pitch from one another. The bridging members 104 can thus alternate between bridging elements 140a that extend from a first apex 122a to a second apex 122b at a clockwise angle (otherwise known as a negative angle) with respect to the longitudinal axis 110 and bridging elements 140b that extend from a first apex 122c to a second apex 122d at a counter-clockwise angle (otherwise known as a positive angle) with respect to the longitudinal axis 110 of the stent.


The alternating pitch of the circumferential bridge members 104 advantageously prevents the stent 100 from responding with a bias to torsional loading. If all of the bridging elements 104 were alternatively oriented with the same pitch, a torsional load of a given direction may cause the stent to twist and/or to preferentially expand or contract in diameter. With an alternating pitch, the bias to torsional loading can be partially removed. That is, alternating the pitch allows the tendency for one bridging member 104 to rotate clockwise to be balanced by the adjacent bridging member's tendency to rotate counterclockwise. Further, having alternating pitch allows the stent 100 to accommodate significant axial, bending, or torsional deformation with relatively low amounts of strain because the loads can be distributed across the bridging elements 140. In some embodiments, the pitch of adjacent bridging members 104 is exactly opposite so as to fully balance out the torsional load across the stent 100. In other embodiments, a desired amount of twist can be purposefully imparted into a first section of the stent 100 and balanced out in another section of a stent 100. In still other embodiments, the stent can include an overall twist caused by an unbalanced pitch. Imparting an intentional twist into all or a section of the stent 100 might be important for matching a twist in a particular anatomy.


Referring to FIG. 4, a bridging element 140 can extend between each pair of internal apices 122c and 122d of expandable members 102. The circumferential bridging element 140 can have a length l as measured from apex 122A to apex 122B. Moreover, the angle between the length of the strut element 601 and a line extending parallel with the longitudinal axis of the strut can be offset by a circumferential angle θ. The angle θ can be used to describe the change in circumferential position traversed by a circumferential bridging element 140.


Flexibility


The bridging members 104 can be used to influence the axial flexibility of the stent 100 when subjected to various loads. Flexibility is particularly important for those portions of the stent that approach or cross a ligament, bone, muscle or other anatomical feature that may alter or influence the response characteristics of the treated vessel.


Referring to FIG. 5, as the stent 100 bends axially, the bridging elements along the outer curve 502 will spread apart, while the bridging elements along the inner curve 504 will draw closer together. Thus, as the length of a bridging element is increased, the longitudinal flexibility of the stent will increase because the bridging elements will be able to spread apart further along the outer curve 540. Likewise, the greater the angle θ, the greater the longitudinal flexibility of the stent because each bridging member 140 has a greater ability to stretch along the outer curve 540. As with the strut elements 120 described above, increasing the width w and thickness t of the bridging elements 140 tends to increase the overall stiffness of the structure, and thus adversely impact axial flexibility of the structure. Again, increasing the number of such elements 140, while correspondingly reducing the width of individual elements, allows for bending loads to be distributed more uniformly throughout the structure, and generally improve axial flexibility.


Radial Stiffness


The bridging elements contribute to radial stiffness by a relation of l*θ. As θ varies from an axial orientation to a circumferential orientation, the contribution to radial stiffness ranges from low to high. Bridging elements that are axially oriented have no impact, as they simply translate in a radial direction as the stent is expanded, contracted, or exposed to hoop forces. Bridging elements that are circumferentially oriented, however, are oriented in the same direction as hoop forces, contribute to carrying hoop loads, and therefore increase hoop stiffness of the structure. The magnitude of this effect is proportional to the length l of the bridging element 140; very short bridging elements have little impact at all, while longer bridging elements have an increasing impact.


Rotating/Foreshortening


Stents commonly experience changes in orientation or length during the transition from constrained to expanded, or the vice versa. For example, a decrease in length can occur between the constrained stent and the expanded stent, called foreshortening. One component of foreshortening results from the change in angle of the struts 120 comprising the expandable members 102 as the strut is expanded.


The bridging members 140 can compensate for some of the foreshortening experienced by the structural elements. As the length l and the angle θ of the bridging elements 140 decrease, the difference in length between the constrained and expanded condition of the stent 100 also decreases. Minimizing the amount of foreshortening is generally desirable to improve the predictability and accuracy of deployment and positioning. Thus, compensating for foreshortening provides motivation to moderate the length l and angle θ of the bridging members 104.


Further, as length l and angle θ decrease, the expandable ring members 102 will have a decreasing tendency to rotate relative to each other as the stent expands or contracts. Relative rotation between expandable ring members 102 can cause the stent to be unstable, disrupt the surrounding tissue, and/or exert undesirable forces or strain on the surrounding structures, providing further motivation to moderate the length and angle θ. Moreover, because the angle θ changes as the stent is expanded or constrained, the relative rotational twisting experienced between adjacent expandable ring members 102 during expansion or constraining also increases.


Examples


As an extreme example, consider holding the length l constant and varying the angle θ in a hypothetical series of different designs. In a first design, referring to FIG. 6A, as the angle θ approaches 0°, the bridging elements 140 approach an orientation parallel to the longitudinal axis of the stent. At this extreme, the bridging elements 140 have virtually no contribution to the radial strength of the stent. As the stent expands or contracts, assuming that the bridging elements 140 maintain their horizontal orientation, there is zero relative rotation between adjacent expandable ring members. Further, these horizontally oriented bridging elements inhibit bending flexibility.


In a second design, referring to FIG. 6B, as the angle θ approaches 90°, the bridging elements 601 approach a circumferential orientation. At this extreme, the bridging elements 601 have a significant contribution to the radial strength of the stent. Moreover, as the stent expands or contracts, the relative rotation between expandable ring members can be significant (it increases with increasing bridging element length). And at this extreme, the circumferentially oriented bridging elements 140 promote bending flexibility.


Stent Characteristics as a Whole


The stent 100 can be formed from a superelastic material. In one specific aspect, the superelastic material is Nitinol, an intermetallic compound having approximately 50.8 atomic percent Nickel and the balance Titanium. Nitinol has the unique properties of shape memory and superelasticity, and in this application is designed to take advantage of the material's ability to withstand unusually high levels of strain (up to 8% or more), without experiencing plastic deformation. The material can have an unusually pronounced hysteresis effect in its stress-strain relationship: when subjected to loading, stresses are relatively high, as they reach the upper plateau (UP) where a phase change from austenite to martensite occurs. When the material is unloaded, stresses are relatively low, as seen in the lower plateau (LP) where the material transforms from martensite to austenite. The magnitude of the difference between UP and LP stresses is determined by material composition, as well as thermal and processing history. In some embodiments, the transition temperature for the material, known as the Austenite Finish (Af) temperature is preferably set between 10 degrees and 37 degrees C. Preferentially, the Af temperature is set close to body temperature to maximize the hysteresis effect of the material, increasing the difference between UP and LP. As such, forces exerted by the stent as it unloads (expands) from its constrained state are minimized. This force, described as Chronic Outward Force (COF), is controlled by the LP stress. Conversely, the forces exerted by the stent when it is loaded (subjected to external compression) are maximized. This force, described as Radial Resistive Force (RRF), is controlled by the UP stress.


When all internal apices 122 of a stent are connected together through a bridging element 140, as shown in FIG. 1, the stent can be termed a “closed cell” strut. Advantageously, by having a “closed cell” as opposed to an “open cell” stent can prevent webbing or spurs of a lesion from prolapsing through the struts to compromise the lumen. Conversely, if a stent is “open cell,” in which some internal apices are unconnected, the stent can move more freely for enhanced flexibility. In some embodiments, the modules of the stents described herein can be modified such that a closed cell architecture is provided in some stent regions and an open cell architecture is provided in other regions. For example, the areas of the stent expected to lie within the regions of localized constriction can have a closed cell architecture while other areas have an open structure.


Stents are typically placed within a lumen to restore patency of a compromised lumen, resolve obstructions caused by disease or anatomical formations, and thereby improve flow. Obstructions within the lumen are often irregular or non-uniform in nature, and consequently it is desirable for the stent to provide uniform support throughout its contact area with the vessel, and minimize the area of any unsupported regions. “Scaffolding performance” is a term used to describe the ability of a stent to serve this purpose. Cell size, the area bounded by a closed region of struts or bridges, is one measure of scaffolding performance. Minimum inscribed circle (MIC), the smallest circle (or more properly, sphere) that can fit through the structural elements of the stent, passing from inside its cylindrical form to outside, is another measure. Both cell size and MIC can vary as the stent is expanded, stretched, twisted, or otherwise deformed. Ideally, both are minimized throughout any expected loading conditions experienced by the stent. Scaffolding performance tends to improve with the number of elements around the circumference and along the length; more elements of a smaller size will provide more uniform coverage and support for small and irregular obstructions that the stent may oppose in the lumen.


Typically, designs that provide excellent scaffolding characteristics and outward support are also relatively axially stiff, and therefore experience high local strains with localized axial displacement, bend, or torsional loads. Conversely, designs that offer excellent axial and bend flexibility typically suffer from poor local scaffolding performance as local regions of the stent may flex apart to accommodate a bend, this same local flexion typically exposes a gap in scaffolding support, often at the very region where it is most needed. The stents described herein addresses each of the concerns to provide a superior platform for treatment of various anatomical areas of the body.


Advantageously, the properties of the stents described herein can be customized along the length of the device to correspond to the physiology that is common with a particular anatomy or condition. Thus, each stent can have multiple sections, each section including modules that are modified to have a particular property.



FIG. 6C shows a chart of the effect of several variables on the flexibility, stiffness, rotation, and scaffolding, where + indicates positive correlation, ++ indicates strong positive correlation, − indicates negative correlation, −− indicated a strong negative correlation, and 0 indicates no influence. Thus, for example, to make a section more axially flexible, the bridge members can include a greater number of bridge elements circumferentially or have elements with a longer length, a higher pitch, a lower width, or a lower thickness. Likewise, expandable members can have a higher number of struts circumferentially, or have struts elements with a longer length, lower width, or lower thickness. To make a section more radially stiff, there can be fewer strut elements in the expandable ring member, or each strut element can have a shorter length, a higher width, or a higher thickness. Likewise, the bridging members can have a lower number of bridging elements circumferentially, or each bridging element can have a higher length, a higher pitch, a higher width, or a higher thickness. To make a section less rotatable, the bridging elements can have a shorter length or a lower pitch. Scaffolding performance is improved by increasing the number of elements around the circumference, and along the length, and minimizing the freedom of these elements to move apart from each other as the stent is expanded, placed in a bend, or otherwise deformed. These parameters can be adjusted and balanced so as to optimize the performance of the stent for a given indication.


IVCS Stents


Chronic venous insufficiency (CVI) is a disease in which the function of the venous system is compromised. As a result of CVI, blood tends to pool in the lower extremities, and insufficient blood may be returned to the heart for re-oxygenation. The patho-physiology of CVI commonly involves veins of the lower extremities and/or pelvic area: the femoral veins, iliac veins, and inferior vena cava. CVI is associated with deep vein thrombosis (DVT), a condition resulting from clotting of stagnant blood in the deep vein system. CVI is also associated with varicose veins in the superficial venous system, a condition relating to incompetent venous valves. CVI is a progressive condition that can result in leg pain and swelling, edema, and ulcers of the leg or ankle.


A condition known as iliac vein compression syndrome (IVCS), also known as May-Thurner syndrome, or pelvic spur syndrome is recognized as a cause of venous thrombo-occlusive disease. Referring to FIG. 7A, IVCS is commonly observed at the confluence of the common iliac veins, where the right iliac artery 702 crosses the left common iliac vein (LCIV) 704. As shown in FIGS. 7B and 7C, the IVCS can cause compression of the LCIV 704 between the artery 716 and the spine 718. Symptomatic chronic nonmalignant obstructive lesions most commonly occur in region 101 between the confluence of the iliac veins to the inguinal ligament. Further, compression and consequent webbing or spurs are most common at region 101A where the right iliac artery 702 crosses the left common iliac vein. A similar anatomical condition can occur at region 101C where the left internal iliac artery crosses the external iliac vein. In these regions, chronic pulsatile compression is believed to cause the formation of intraluminal venous webs or spurs. These anomalies have been described as chronic nonmalignant obstructive lesions.


Such obstructive lesions may be observed in clinical practice by diagnostic procedures including venography or intravascular ultrasound. It is believed that these lesions are an important contributor to the cascade of events leading to CVI of escalating severity. These lesions may be dilated by balloon venoplasty in an attempt to restore venous flow, but this technique has been found to provide inadequate resolution in many cases. Studies have found that treating these lesions with intravenous stents is a safe and effective therapy that is more durable than balloon venoplasty alone. To date, no stent has been designed specifically to treat obstructive lesions of the pelvic veins. Therefore, stents to help treat the particular issues related to obstructive lesions of the pelvic veins are needed.


Referring to FIG. 8, a stent 800 for treatment of IVCS may be preferentially designed by varying the parameters described herein. The stent 800 can have a length that covers the region 101, e.g., be at least 130 mm in length. The expanded diameter of the stent 800 can be between 120 nm and 20 mm, such as approximately 14 mm.


The stent 800 can include several expandable members 102 connected by bridging modules 104. The stent can include sections 801A, 801B, 801C, and 801D that are configured to line up with regions 101A, 101B, 101C, and 101D, respectively, of the artery.


Section 801A can be configured to maximize stiffness or resistance to compressive force in the region of the right iliac artery compression 101A. Likewise, section 801C can be configured to maximize stiffness or resistance to compressive force in the region of the left internal artery compressions 101C. Thus, for example, the strut length of the strut elements in the ring members 102 can be decreased and/or the strut thickness can be increased in sections 801A and 801C relative to section 801B so as to maximize stiffness in those areas. For example, there can be 30 to 60 struts, such as 48 struts in each ring member 102 of sections 801A and 801C. Further, the length of the struts in each ring member 102 of sections 801A, 801C can be between 1 and 4 mm, such as approximately 2.1 mm. The width of the struts in each ring member 102 of sections 801A and 801C can be between 0.1 mm and 0.3 mm, such as approximately 0.15 mm. The thickness of the struts in each ring member 102 of sections 801A, 801C can be between 0.1 mm and 0.5 mm, such as between 0.2 mm and 0.4 mm, such as approximately 0.36 mm. Moreover, the length of the bridging elements 140 of bridging members 104 in sections 801A and 801C can be increased and/or the angle θ can be increased relative to bridging members 104 in section 801B.


Further, section 801D can be configured to maximize flexibility in the region where the LCIV approaches or crosses the inguinal ligament (region 101D). In one embodiment, the total expanded circumference of the stent is 14 mm*π=44 mm, and the length of the bridging elements of the bridging modules 104 of section 801D is approximately 4.4 mm. The angle θ, therefore, is approximately 10% of the circumference, or 36°, when the stent is in its expanded configuration. In the constrained condition, the circumference of this stent is 3.2 mm*π=10 mm, so the constrained θ of bridging modules 104 in section 801D is 44% of the circumference, or 160°. As this stent is expanded or constrained, adjacent expandable ring segments in section 801D undergo rotation of the difference in the expanded and contracted θ, 160° minus 36°, or 124°. Further, the struts of the ring members 102 can be configured to have a length of approximately 1-4 mm. These design parameters are chosen so as to enhance flexibility without compromising scaffolding performance.


Femoral Artery Stents


Arterial disease occurs when the natural lumen of an artery narrows or closes, such as when fibro-fatty deposits or calcified plaques grow within the layers of the artery and spread throughout the arterial system. Consequences of coronary arterial disease may range from angina to myocardial infarction and sudden death.


The superficial femoral artery (SFA) is commonly affected by peripheral arterial disease that may be associated with symptoms ranging from mild claudication and difficulty walking to chronic limb ischemia and partial amputation. FIGS. 9A-9C show the femoral arteries 900 in relation to surrounding muscles 902 and skeletal landmarks 904. As the external iliac artery passes posterior to the inguinal ligament 906, its name changes to the common femoral artery 910, which branches (at 912) into the profunda 914 and the superficial femoral artery 916. The profunda 914 supplies blood to the thigh and the superficial femoral artery 916 carries blood to the lower limb.


The SFA is unique in the human arterial system, as it traverses the thigh region with few branches, serving to deliver oxygenated blood to the lower limb by way of the popliteal and tibial arteries. Transiting from the region of the hip to the knee, the SFA passes through several muscle groups, and is subjected to one of most dynamic and mobile environments in the human anatomy. While disease in the SFA can be localized, it is frequently diffuse, commonly spanning 10 cm or more.


The superficial femoral artery is effectively pinned in two major locations: in area 930A near its origin in the area of the inguinal ligament 910 and the branch 912, and in area 930C near its terminus in the area of first genicular arteries 922 and the Hunters canal 924. Between these points, in region 930C, the vessel can be quite mobile, limited to some extent by minor branch vessels, often to a greater extent by rigid calcifications within the diseased regions of the vessel. The areas of the vessel that are less constrained—for example, the area 930B between the inguinal ligament and hunters canal and the area 930D, and away from areas of localized calcification—may be subjected to highly localized deformations including twisting, stretching, and/or compression with flexion of the limb.


The dynamic challenges of this disease prone area of the SFA create a severe fatigue environment for metallic implants intended to improve lumen diameter and distal perfusion. Stents placed in this region have commonly been found to fracture, raising concern about such implants failing to perform their function, creating injury, or causing additional risks to the patient. Accordingly, a stent that is capable of withstanding such an environment is needed.


Referring to FIG. 10, a stent 1000 for treatment of the femoral arteries includes alternating circumferential bridging members 104 and expandable ring members 102. The stent can include sections 1030A, 1030B, 1030C, and 1030D that are configured to line up with regions 930A, 930B, 930C, and 930D, respectively, of the artery. Thus, the stent 1000 can have an expanded diameter of slightly more than the diameter of the femoral artery to provide sufficient outward force. For example, the stent 1000 can have an expanded diameter of greater than 7 mm, such as approximately 8 mm.


The sections 1030A and 1030C intended to be placed in the pinned area of the adductor hiatus and canal can be configured to be of higher strength or stiffness relative to sections 1030B and 1030D. For example, the wall thickness can be increased relative to sections 1030B and 1030D and/or the ratio between the wall thickness and the strut width can be increased relative to sections 1030B and 1030D. Furthermore, to increase the hoop stiffness in this area, the length and angle of the bridging elements may be increased. Furthermore, to increase the hoop stiffness in this area, the length and angle of the bridging elements may be increased.


Further, section 1030B of the stent 1000 that is intended to be placed in the highly mobile region 930B between the profunda 804 and the adductor hiatus 805 and in the mobile region 930D can be configured to be more flexible relative to sections 1030A, 1030C. For example, the alternating circumferential bridging members can be designed to allow increased flexibility by increasing the length and angle θ of bridging elements in the bridging members 104 relative to sections 1030A and 1030C.


Coronary Artery Stents


Coronary arterial disease is among the most important areas of interventional medicine. Traditional stenoses of the coronary arteries have been treated with balloon expandable stents because of their high strength, ease of use, and versatility. Referring to FIG. 11, the modular stent described herein could be useful in the coronary arteries 1100 for bifurcation 1102 of the left main (LM) artery 1101 to the left anterior descending (LAD) artery 1104, the left main artery to the circumflex (CX) artery 1103, or are in the region of side branches between right coronary artery (RCA) 1110, LAD 1104, or CX 1103 and corresponding diagonal branches along their length. Similarly, self expanding stents could be used for stenting the LM 1101 itself, and potentially the ostium 1115 of the LM 1101 and RCA 1110 at the location of the aortic root 1114. Particularly in these areas, it is critical that the stent accommodate significant variation in shape in-situ, i.e., the final contour of the implanted stent may need to be significantly non-cylindrical and include abrupt changes in local diameter or cross section.


Referring to FIGS. 12A-12B, a stent 1200 for treatment of coronary artery disease includes alternating circumferential bridging members 104 and expandable ring members 102. The stent 1200 is configured to abruptly change one or more of its shape, contour, local diameter, or cross sectional profile to accommodate for the changes of the coronary arteries. In one embodiment, shown in FIG. 12A, the stent 1200 includes a section 1201 and a section 1202. Section 1201 can be configured to be positioned near an ostium or the origin of a branch vessel. Accordingly, section 1201 can be more flexible than section 1202. Thus, for example, the bridging elements of the bridging members 104 can be longer in section 1201 than in section 1202. Further, the pitch of the bridge members 104 can be increased relative to section 1202. Additionally, section 1202 can be configured to provide more uniform vessel support than section 1201 and/or can be configured to provide drug delivery to the remainder of the stented coronary artery. The shorter bridging elements and small pitch relative to section 1201 can provide increased support in section 1202.


In another embodiment, shown in FIG. 12B, the coronary artery stent 1200 includes a section 1203 between adjacent sections 1204A and 1204B. Section 1203 can be configured to be located at the site of a branch vessel, while sections 1204A and 1204B can be configured to be proximal and distal to the branch location. Accordingly, section 1203 can be configured to be more flexible than sections 1204A and 1204B. Thus, bridging elements of the bridging members 104 in region 1203 can be longer and/or have a higher pitch than the bridging elements in regions 1204A and 1204B.


Renal Artery Stents


Referring to FIG. 13, the rental arteries are prone to arterial disease, particularly in the ostium 1304. However, stenting can be difficult because the renal arteries 1303 are relatively mobile during the respiratory cycle. The kidney 1102 can move several millimeters during the respiratory cycle, while the aorta 1101 moves separately. The renal arteries 1303, joining the kidneys to the aorta, may therefore experience significant bending, angulation, or displacement between inhalation and expiration. Traditional inflexible stents may adversely impact the normal anatomy in this region, while flexible stents may experience large cyclic deformations and strains, potentially resulting in fracture. It is therefore important to provide a renal artery stent that can be sufficiently flexible, can accommodate the complex shape of the renal ostium, and can provide substantial radial stiffness for the body of the renal artery.


Referring to FIG. 14, a renal artery stent 1400 includes alternating circumferential bridging members 104 and expandable ring members 102. The stent includes a section 1401 configured to be placed at the ostial end of the rental artery and a section 1402 configured to be placed along the rest of the artery. Thus, section 1401 can be more flexible than section 1402 to accommodate for the shape of the ostium. Conversely, section 1402 can be configured to provide higher strength or stiffness than section 1401 to adequately support the rest of the artery. Thus, for example, section 1401 can include longer bridging elements than section 1402, allowing for significant flaring of section 1401 to adequately cover the ostium 1304. Further, section 1402 can include feature shorter and stiffer struts than section 1401.


Carotid Artery Stents


Referring to FIG. 15, the carotid arteries 1500 include the common carotid artery 1501, the internal carotid artery 1503, and the external carotid arteries 1502. The common carotid artery 1201 splits into the internal carotid artery 1503 which delivers flow to the brain, and external carotid arteries 1502 that deliver flow to the other areas of the head and face. The bifurcation 1504, where the common branches into the internal and external carotid arteries, is also described as the carotid bulb or carotid sinus. Carotid arterial disease commonly involves substantial plaque deposits and flow limiting narrowing in the common, and branch carotid vessels, and therefore commonly involves the sinus region. There are several important structures in the region 1530B of the carotid sinus including the baroreceptors in the adventitial layer of the carotid sinus. These baroreceptors are mechanoreceptors modulate the activity of the sympathetic and parasympathetic nervous systems on the basis of pressure and/or stresses in the vessel wall. Angioplasty and stenting in this region can create hemodynamic instability, with detrimental effects on baroreflex, and consequent hypotension or hypertension. Conventional stents, with uniform outward force along the length of the structure, may exacerbate this effect. Accordingly, a stent is needed with enough support so support a lesion in the carotid artery, but enough flexibility to avoid hemodynamic instability.


Referring to FIG. 16, a carotid artery stent 1600 includes alternating circumferential bridging members 104 and expandable ring members 102. The stent includes sections 1630A, 1630B, and 1630C, which correspond to regions 1530A, 1530B, and 1530C, respectively, of the carotid artery. Region 1630B can be designed to allow for the abrupt change in diameter and shape in region 1530B while minimizing disruption of the carotid sinus. For example, the radial stiffness of section 1630B can be reduced and/or the flexibility of section 1630B can be increased relative to neighboring sections 1630A and 1630C.


Fistula Stents


Referring to FIGS. 17A and 17B, the stent described herein could be used at the junction of hemodialysis fistulae 1301 or grafts 1302. In these applications, a stent may need to be placed at the junction of an artery, vein, and/or synthetic graft, and therefore assume an abrupt angle. Furthermore, the stent may have to accommodate a significant diameter change at the site where the fistula or graft joins the native artery, making the modular stent described herein advantageous over traditional stents.


Tracheal Stents


Referring to FIGS. 18A-18B, the trachea 1901 branches into the right and left main stem bronchi 1903, which further branch into lobar bronchi 1904 to feed the lungs. The main stem and lobar bronchi are circumferentially supported by irregular plates of hyaline cartilage. In the main stem, lobar bronchi and below, the cartilage 1910 is partially circumferential, taking the shape of the letter “C,” with a fibrous membrane 1911 between the ends of the “C.” When foreign matter, phlegm, or other debris becomes lorded in the bronchi or trachea, a cough reflex is triggered. The response of the human trachea during a cough is illustrated in FIGS. 19A-19B. When a cough occurs, the soft tissue in this region allows the substantially circular cross section of the trachea 2001 to collapse into a narrowed crescent shaped channel 2002. The reduced cross sectional area increases the velocity of the air exiting the lungs through this space, helping to propel material out of the trachea. The airways may become obstructed in the case of tumor growth in the region of the lungs or surrounding structures, causing compression of infiltration of the bronchi or trachea.


Stents can be placed in the trachea as a palliative or restorative therapy. Such a stent may provide outward forces to expand the lumen of the airways, prevent compression and/or ingrowth of the tumor, and/or deliver chemotherapeutic or other agents locally. Stents commonly used in this indication have several shortcomings. For example: silicone or polymer based stents have low outward force and can migrate or be expectorated; other stents designed primarily for cardiovascular use have been deployed with limited success, as these devices lack sufficient radial stiffness, thus allowing undesirable compression. Importantly, conventional stents are typically designed to have uniform radial outward forces along the length of the stent, which creates an incompatibility with the normal physiological and/or biomechanical movement of the airway. Furthermore, conventional stents may interrupt or degrade the normal mucociliary transport system of the bronchi and trachea with struts or coverings that are oriented in such a way as to inhibit the normal flow of mucus. Accordingly, a stent is needed that addresses some or all of these limitations.


Accordingly, a modular stent as described herein could be used in the trachea. The circumferential bridging elements could accommodate the need for the airways to transform between a substantially circular cross section to a substantially crescent shaped cross section during a cough. For example, an array of struts axially aligned in a circumferential band ranging up to 180 degrees of the circumference, and oriented toward the dorsal aspect of the airway, can be designed to be more flexible than the struts in an axial band oriented toward the ventral aspect of the airway. The normal configuration of the mucosal epithelium is spiral in nature. Further, the smooth muscle surrounding the airways tissue is arranged in a helical orientation. The epithelium and cilia follow the orientation of the innermost smooth muscle layer. In a preferred embodiment of the present invention, the circumferential bridge elements are oriented in such a way as to be consistent with this orientation. As such, an embodiment for this indication may favor circumferential bridges that are all oriented in the same direction, rather than alternating in direction along the length. Furthermore, the bridges are preferentially oriented in a direction that is closer to axial than circumferential, thus promoting functional mucociliary transport.


Methods of Use


In operation, the stents described herein can be placed in the anatomy of interest. In some embodiments, the physician can first inject a radiopaque contrast medium into the vessel of interest to visualize the path and caliber of the subject veins. Alternatively, or in addition, the physician may introduce an intravascular ultrasound (IVUS) catheter into the vessel of interest to study the cross section of the lumen at all points along its length. The IVUS catheter can be specifically designed to work in conjunction with the stent and delivery system described herein. Preferentially, the IVUS probe would be contained within the profile of a standard 0.035″ guidewire, and could therefore be used to replace the conventional guidewire for balloon and stent delivery while providing opportunity for imaging throughout the procedure.


Using the radiopaque markers and/or IVUS guidance, the physician can place a high pressure balloon at the site of the constriction and inflate to a pressure sufficient to dilate the narrowed area. This procedure may be repeated multiple times and at multiple locations to achieve a satisfactory result.


The stent can be constrained within a flexible sheath, preferably such that the sheath is compatible with an introducer sheath having a profile of 10 French or less. In some embodiments, the stent is constrained within this sheath at the time of manufacturing and packaging. Alternatively, the stent can be constrained within a capsule that is packaged separately from the delivery sheath, and coupled with the delivery device before insertion into the patient.


The physician can place a guidewire, such as a 0.035″ guidewire, across the site of the target vessel. The delivery system can then be advanced over the guidewire to the target site. The stent can be positioned in the desired location using X-Ray and/or ultrasound guidance.


An actuation mechanism at the proximal end of the delivery system can then be used to retract the outer constraining sheath and allow the stent to expand to its memory diameter. Preferably, the stent will be held fixed relative to the vessel by means of an inner member that engages the stent and is held axially fixed during sheath retraction. The constraining sheath may be designed to retract in a “tip to hub” direction, thereby first expanding and anchoring the end of the stent farthest from the operator. Alternatively, the constraining sheath may be designed to retract from “hub to tip” direction, thereby first expanding and anchoring the end of the stent closest to the operator first. Because placement at the confluence is critical, the direction of approach determines the preferred direction of unsheathing. With the typical antegrade approach, the hub end of the delivery system is near the femoral vein, the tip end is near the confluence, and the preferred direction of deployment is therefore tip to hub. For a more unusual jugular or contralateral approach, the tip end of the stent would be near the femoral vein, the hub end near the confluence, and the preferred direction of deployment would therefore be hub to tip.


After the stent has initially expanded and anchored, it may be advantageous to confirm accurate placement with ultrasound or X-Ray guidance. Further, the stent may contain markers to aid the physician to locate the proximal and distal ends of the stent, as well as any unique features along the length of the stent, or around its circumference. This can be particularly important to denote the location of stent regions with modulated stiffness or flexibility as described above. Radiopacity enhancing features may include coatings, tabs, rivets, inserts, or other features composed of metals including tantalum, platinum, gold, palladium, silver, or combinations thereof. Alternatively or in addition, it may also be advantageous to similarly provide enhanced echogenecity at certain locations of the stent to enhance visualization of selected features during ultrasound diagnostic procedures.


Using visualization techniques, if the placement of the stent is not optimal, the physician may readvance the constraining sheath to recapture the deployed segment of stent, reposition the delivery system, and attempt the deployment again. The ability to recapture the stent is another benefit of the closed cell architecture described above, and is another advantage to connecting all of the internal apices, particularly in the region of the stent that is first expanded. After the stent has been confirmed to be anchored in the intended location, the sheath is fully retracted, releasing the stent from the delivery system into position within the target vessel.


Once the stent has unloaded from its constrained diameter, it will contact the vessel. The chronic outward force of the stent will cause the vessel diameter, particularly at the point of the lesion, to enlarge to restore flow through the vessel. As a final step, it can be advantageous to inflate a balloon within the stent, particularly in the region of the subject obstructive lesions. The balloon can assist in expanding the stent, even past its normal expanded diameter. When the balloon is deflated, the stent is again subjected to loading stresses, and therefore resists recoil of the vessel according radial resistive force (RRF) driven by the higher stress response of the upper plateau. With this method, the outward forces localized in the area of the obstructive lesion are maximized to ensure maximum luminal gain and relief from the symptoms associated with IVCS.


While numerous embodiments of the present invention have been shown and described herein, one of ordinary skill in the art will appreciate that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. In addition, the intended uses of the present invention include a variety of medical applications as well as other applications where highly precise, compact devices for fluid transport are needed. It should be understood that various alternatives to these embodiments of the invention described herein may be employed in practicing the invention. It is intended at the following claims defined the scope of the invention and it methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A method of inserting a stent, comprising: inserting a stent into a vessel, the stent comprising a first section and a second section, wherein the first section is more flexible along a longitudinal axis of the stent than the second section, the first section and the second section each including:a plurality of expandable modules, each expandable module including a plurality of strut elements that join together at a plurality of apices; anda plurality of bridging modules, each bridging module including bridging elements having a constant pitch that connect only an apex of a first module with only an apex of a second module such that every apex in an expandable module is connected to an apex in an immediately adjacent expandable module by a bridging element, wherein the plurality of bridging modules are arranged to alternate along the longitudinal axis between clockwise bridging modules and counterclockwise bridging modules, the clockwise bridging modules including bridging elements that extend at a fixed clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a fixed counterclockwise angle with respect to the longitudinal axis, wherein there are a greater number of bridging elements in the plurality of bridging modules around a circumference of the first section than the number of bridging elements in the plurality of bridging modules around a circumference of the second section wherein the second section is more radially stiff than the first section, the method further comprising aligning the second section with a specific region of the vessel that requires radial stiffness to counteract crushing force caused by surrounding anatomy; andaligning the first section with a specific region of the vessel that requires axial flexibility to accommodate surrounding anatomy.
  • 2. The method of claim 1, wherein the vessel is a left iliac vein, and wherein the specific region is proximate to where a common femoral vein crosses underneath an inguinal ligament.
  • 3. The method of claim 1, wherein the vessel is a vein, and wherein the specific region of the vessel that requires axial flexibility to accommodate surrounding anatomy is proximate to where a common femoral vein crosses underneath an inguinal ligament and the second section is more radially stiff than the first section and adapted and configured to provide a radial stiffness to counteract a crushing force caused by a inguinal ligament with the vein wall.
  • 4. The method of claim 1 the stent further comprising a third section having expandable modules and bridging modules as in the first section, the third section positioned such that the second section is between the first section and the third section.
  • 5. A method of inserting a stent, comprising: inserting a stent into a vessel, the stent comprising a first section and a second section, wherein the first section is more flexible along a longitudinal axis of the stent than the second section, the first section and the second section each including:a plurality of expandable modules, each expandable module including a plurality of strut elements that join together at a plurality of apices;a plurality of bridging modules, each bridging module including bridging elements that extend only from an apex of a first expandable module to only an apex of an immediately adjacent second expandable module wherein the first expandable module is connected with the second expandable module only by said bridging elements, wherein the first section of the stent has a greater number of bridging elements around a circumference of the first section than the number of bridging elements around a circumference of the second section;wherein the plurality of bridging modules are arranged to alternate along the longitudinal axis between clockwise bridging modules and counterclockwise bridging modules, the clockwise bridging modules including bridging elements that extend at a clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a counterclockwise angle with respect to the longitudinal axis, wherein the clockwise bridging modules including bridging elements that extend at a fixed clockwise angle with respect to the longitudinal axis, and the counterclockwise bridging modules including bridging elements that extend at a fixed counterclockwise angle with respect to the longitudinal axis;aligning the first section with a first specific region of the vessel that requires axial flexibility to accommodate surrounding anatomy; andaligning the second section with a second specific region of the vessel to provide radial stiffness to counteract a crushing force imparted by a surrounding anatomy.
  • 6. The method of claim 5, wherein the vessel is a left iliac vein, and wherein the first specific region is proximate to where a left common iliac vein crosses an inguinal ligament.
  • 7. The method of claim 5, wherein the vessel is a vein, and wherein the specific region of the vessel that requires axial flexibility to accommodate surrounding anatomy is proximate to where a left common iliac vein crosses an inguinal ligament and the second section is more radially stiff than the first section and adapted and configured to provide a radial stiffness to counteract a crushing force caused by a inguinal ligament with the vein wall.
  • 8. The method of claim 5 wherein the length of the first section and the second section is selected to be sufficient to position the stent along a portion of the patient's venous vasculature to treat a cause of a venous thrombo-occlusive disease.
  • 9. The method of claim 8 wherein the venous thrombo-occlusive disease is an occurrence of iliac compression disorder.
  • 10. The method of claim 5 wherein the difference in the fixed clockwise angle and the fixed counterclockwise angle partially removes a bias to torsional loading in the stent during use.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 61/258,145, filed Nov. 4, 2009 entitled “Stent for Relief of Pelvic Venous Outflow Obstruction and Methods for Use Thereof.” This application also claims priority to U.S. Provisional Patent Application No. 61/290,836, filed on Dec. 29, 2009 entitled “Alternating Circumferential Bridge Stent Design and Methods of Use Therefore.” This application also claims priority to U.S. Provisional Patent Application No. 61/391,462, filed on Oct. 8, 2010 entitled “Alternative Circumferential Bridge Stent Design and methods of Use Therefore.” These applications are herein incorporated by reference in their entirety.

US Referenced Citations (728)
Number Name Date Kind
3593854 Swank Jul 1971 A
3659593 Vail May 1972 A
3765536 Rosenberg Oct 1973 A
3765537 Rosenberg Oct 1973 A
3788328 Alley et al. Jan 1974 A
3807401 Riggle et al. Apr 1974 A
3843974 Miller et al. Oct 1974 A
3874388 King et al. Apr 1975 A
3935111 Bentley Jan 1976 A
3952747 Kimmell, Jr. Apr 1976 A
3953566 Gore Apr 1976 A
3970565 Ahlstrand et al. Jul 1976 A
4007743 Blake Feb 1977 A
4014318 Dockum et al. Mar 1977 A
4016884 Kwan-Gett Apr 1977 A
4073723 Swank et al. Feb 1978 A
4101984 MacGregor Jul 1978 A
4115277 Swank Sep 1978 A
4157965 Raible Jun 1979 A
4303530 Shah et al. Dec 1981 A
4319580 Colley et al. Mar 1982 A
4353996 Marconi et al. Oct 1982 A
4374669 MacGregor Feb 1983 A
4425908 Simon Jan 1984 A
4444198 Petre Apr 1984 A
4447227 Kotsanis May 1984 A
4457487 Steigerwald Jul 1984 A
4494531 Gianturco Jan 1985 A
4523592 Daniel Jun 1985 A
4542748 Roy Sep 1985 A
4553545 Maass et al. Nov 1985 A
4565823 Ohata et al. Jan 1986 A
4586501 Claracq May 1986 A
4592356 Gutierrez Jun 1986 A
4616656 Nicholson et al. Oct 1986 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4627836 MacGregor Dec 1986 A
4642089 Zupkas et al. Feb 1987 A
4643184 Mobin-Uddin Feb 1987 A
4650466 Luther Mar 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4664682 Monzen May 1987 A
4666426 Aigner May 1987 A
4666543 Kawano May 1987 A
4676771 Henke Jun 1987 A
4680029 Ranford et al. Jul 1987 A
4688553 Metals Aug 1987 A
4699611 Bowden Oct 1987 A
4722724 Schocket Feb 1988 A
4727873 Mobin-Uddin Mar 1988 A
4732152 Wallsten Mar 1988 A
4756884 Hillman et al. Jul 1988 A
4760849 Kropf Aug 1988 A
4774949 Fogarty Oct 1988 A
4781177 Lebigot Nov 1988 A
4790329 Simon Dec 1988 A
4793348 Palmaz Dec 1988 A
4795446 Fecht Jan 1989 A
4817600 Herms et al. Apr 1989 A
4826478 Schocket May 1989 A
4828563 Muller-Lierheim May 1989 A
4832055 Palestrant May 1989 A
4858623 Bradshaw et al. Aug 1989 A
4873978 Ginsburg Oct 1989 A
4899543 Romanelli et al. Feb 1990 A
4917089 Sideris Apr 1990 A
4923464 DiPisa, Jr. May 1990 A
4944727 McCoy Jul 1990 A
4946457 Elliott Aug 1990 A
4954251 Barnes et al. Sep 1990 A
4957501 Lahille et al. Sep 1990 A
4969891 Gewertz Nov 1990 A
4969902 Ravo Nov 1990 A
4986279 O'Neill Jan 1991 A
4990156 Lefebvre Feb 1991 A
5018530 Rank et al. May 1991 A
5059205 El-Nounou et al. Oct 1991 A
5071407 Termin et al. Dec 1991 A
5092996 Spielberg Mar 1992 A
5102417 Palmaz Apr 1992 A
5108407 Geremia et al. Apr 1992 A
5108418 Lefebvre Apr 1992 A
5108419 Reger et al. Apr 1992 A
5108420 Marks Apr 1992 A
5127916 Spencer et al. Jul 1992 A
5133733 Rasmussen et al. Jul 1992 A
5147379 Sabbaghian et al. Sep 1992 A
5151105 Kwan-Gett Sep 1992 A
5152777 Goldberg et al. Oct 1992 A
5158533 Strauss et al. Oct 1992 A
5158565 Marcadis et al. Oct 1992 A
5171259 Inoue Dec 1992 A
5190657 Heagle et al. Mar 1993 A
5192286 Phan et al. Mar 1993 A
5192301 Kamiya et al. Mar 1993 A
5195984 Schatz Mar 1993 A
5197978 Hess Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5234458 Metais Aug 1993 A
5257621 Bardy et al. Nov 1993 A
5269924 Rochat Dec 1993 A
5273517 Barone et al. Dec 1993 A
5275622 Lazarus et al. Jan 1994 A
5282823 Schwartz et al. Feb 1994 A
5284488 Sideris Feb 1994 A
5292321 Lee Mar 1994 A
5300086 Gory et al. Apr 1994 A
5311908 Barone et al. May 1994 A
5334217 Das Aug 1994 A
5344427 Cottenceau et al. Sep 1994 A
5350398 Pavcnik et al. Sep 1994 A
5354317 Alt Oct 1994 A
5356432 Rutkow et al. Oct 1994 A
5366504 Andersen et al. Nov 1994 A
5370657 Irie Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5383887 Nadal Jan 1995 A
5413586 Dibie et al. May 1995 A
5415630 Gory et al. May 1995 A
5421832 Lefebvre Jun 1995 A
5423851 Samuels Jun 1995 A
5425744 Fagan et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5443500 Sigwart Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5449382 Dayton Sep 1995 A
5451233 Yock Sep 1995 A
5451235 Lock et al. Sep 1995 A
5464449 Ryan et al. Nov 1995 A
5466216 Brown et al. Nov 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484424 Cottenceau et al. Jan 1996 A
5486193 Bourne et al. Jan 1996 A
5503801 Brugger Apr 1996 A
5507811 Koike et al. Apr 1996 A
5522881 Lentz Jun 1996 A
5527338 Purdy Jun 1996 A
5531788 Dibie et al. Jul 1996 A
5545206 Carson Aug 1996 A
5545210 Hess et al. Aug 1996 A
5549626 Miller et al. Aug 1996 A
5554182 Dinh et al. Sep 1996 A
5562698 Parker Oct 1996 A
5569273 Titone et al. Oct 1996 A
5571166 Dinh et al. Nov 1996 A
5578045 Das Nov 1996 A
5591197 Orth et al. Jan 1997 A
5591224 Schwartz et al. Jan 1997 A
5591227 Dinh et al. Jan 1997 A
5591251 Brugger Jan 1997 A
5593441 Lichtenstein et al. Jan 1997 A
5595909 Hu et al. Jan 1997 A
5599352 Dinh et al. Feb 1997 A
5601595 Smith Feb 1997 A
5603698 Roberts et al. Feb 1997 A
5617854 Munsif Apr 1997 A
5626599 Bourne et al. May 1997 A
5626605 Irie et al. May 1997 A
5632734 Galel et al. May 1997 A
5634474 Grippi Jun 1997 A
5634936 Linden et al. Jun 1997 A
5634942 Chevillon et al. Jun 1997 A
5636644 Hart et al. Jun 1997 A
5637097 Yoon Jun 1997 A
5643320 Lower et al. Jul 1997 A
5643321 McDevitt Jul 1997 A
5649949 Wallace et al. Jul 1997 A
5649950 Bourne et al. Jul 1997 A
5653747 Dereume et al. Aug 1997 A
5653755 Ledergerber Aug 1997 A
5669932 Fischell et al. Sep 1997 A
5669933 Simon et al. Sep 1997 A
5672585 Pierschbacher et al. Sep 1997 A
5681347 Cathcart et al. Oct 1997 A
5693085 Buirge et al. Dec 1997 A
5695518 Laerum Dec 1997 A
5695519 Summers et al. Dec 1997 A
5702421 Schneidt Dec 1997 A
5704910 Humes Jan 1998 A
5709704 Nott et al. Jan 1998 A
5709707 Lock et al. Jan 1998 A
5713853 Clark et al. Feb 1998 A
5713879 Schneider Feb 1998 A
5713921 Bonutti Feb 1998 A
5716408 Eldridge et al. Feb 1998 A
5718717 Bonutti Feb 1998 A
5720764 Naderlinger Feb 1998 A
5722964 Herweck et al. Mar 1998 A
5725552 Kotula et al. Mar 1998 A
5728133 Kontos Mar 1998 A
5733294 Forber et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735892 Myers et al. Apr 1998 A
5741297 Simon Apr 1998 A
5743873 Cai et al. Apr 1998 A
5755663 Larsen et al. May 1998 A
5755776 Al Saadon May 1998 A
5755778 Kleshinski May 1998 A
5755781 Jayaraman May 1998 A
5755790 Chevillon et al. May 1998 A
5766246 Mulhauser et al. Jun 1998 A
5772668 Summers et al. Jun 1998 A
5776142 Gunderson Jul 1998 A
5788661 Japuntich Aug 1998 A
5792179 Sideris Aug 1998 A
5795322 Boudewijn Aug 1998 A
5795325 Valley et al. Aug 1998 A
5795335 Zinreich Aug 1998 A
5799350 Ferek-Petric et al. Sep 1998 A
5800457 Gelbfish Sep 1998 A
5800507 Schwartz Sep 1998 A
5800522 Campbell et al. Sep 1998 A
5810872 Kanesaka et al. Sep 1998 A
5824034 Schmitt et al. Oct 1998 A
5827229 Auth et al. Oct 1998 A
5830224 Cohn et al. Nov 1998 A
5836962 Gianotti Nov 1998 A
5836964 Richter et al. Nov 1998 A
5836969 Kim et al. Nov 1998 A
5843167 Dwyer et al. Dec 1998 A
5843171 Campbell et al. Dec 1998 A
5843176 Weier Dec 1998 A
5846261 Kotula et al. Dec 1998 A
5849004 Bramlet Dec 1998 A
5849034 Schwartz Dec 1998 A
5853420 Chevillon et al. Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5860998 Robinson et al. Jan 1999 A
5861003 Latson et al. Jan 1999 A
5871693 Lindsay Feb 1999 A
5873906 Lau et al. Feb 1999 A
5873907 Frantzen Feb 1999 A
5876432 Lau et al. Mar 1999 A
5879366 Shaw et al. Mar 1999 A
5882340 Yoon Mar 1999 A
5882351 Fox Mar 1999 A
5893869 Barnhart et al. Apr 1999 A
5893887 Jayaraman Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5902333 Roberts et al. May 1999 A
5904703 Gilson May 1999 A
5907893 Zadno Azizi et al. Jun 1999 A
5908447 Schroeppel et al. Jun 1999 A
5910129 Koblish et al. Jun 1999 A
5925061 Ogi et al. Jul 1999 A
5925074 Gingras et al. Jul 1999 A
5928261 Ruiz Jul 1999 A
5928269 Alt Jul 1999 A
5938683 Lefebvre Aug 1999 A
5941896 Kerr Aug 1999 A
5947995 Samuels et al. Sep 1999 A
5954741 Fox Sep 1999 A
5954743 Jang Sep 1999 A
5954767 Pajotin et al. Sep 1999 A
5957940 Tanner et al. Sep 1999 A
5957977 Melvin Sep 1999 A
5965089 Jarvik et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5968053 Revelas Oct 1999 A
5968071 Chevillon et al. Oct 1999 A
5976172 Homsma et al. Nov 1999 A
5980558 Wiley Nov 1999 A
5980564 Stinson Nov 1999 A
5984917 Fleischman et al. Nov 1999 A
5984947 Smith Nov 1999 A
5986169 Gjunter Nov 1999 A
5991657 Kim Nov 1999 A
6001118 Daniel et al. Dec 1999 A
6007558 Ravenscroft et al. Dec 1999 A
6013093 Nott et al. Jan 2000 A
6024096 Buckberg Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6042597 Kveen et al. Mar 2000 A
6046381 Mucke et al. Apr 2000 A
6048329 Thompson et al. Apr 2000 A
6051014 Jang Apr 2000 A
6053932 Daniel et al. Apr 2000 A
6059825 Hobbs et al. May 2000 A
6068645 Tu May 2000 A
6071279 Whayne et al. Jun 2000 A
6077281 Das Jun 2000 A
6077291 Das Jun 2000 A
6080178 Meglin Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6090096 St. Goar et al. Jul 2000 A
6090097 Barbut et al. Jul 2000 A
6090127 Globerman Jul 2000 A
6099493 Swisher Aug 2000 A
6099549 Bosma et al. Aug 2000 A
6117105 Bresnaham et al. Sep 2000 A
6120539 Eldridge et al. Sep 2000 A
6123715 Amplatz Sep 2000 A
6123723 Konya et al. Sep 2000 A
6129755 Mathis et al. Oct 2000 A
6142987 Tsugita Nov 2000 A
6146404 Kim et al. Nov 2000 A
6152946 Broome et al. Nov 2000 A
6171328 Addis Jan 2001 B1
6171329 Shaw et al. Jan 2001 B1
6174322 Schneidt Jan 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6200276 Biesel et al. Mar 2001 B1
6206888 Bicek et al. Mar 2001 B1
6214020 Mulhauser et al. Apr 2001 B1
6214025 Thistle et al. Apr 2001 B1
6214029 Thill et al. Apr 2001 B1
6217600 DiMatteo Apr 2001 B1
6221092 Koike et al. Apr 2001 B1
6231581 Shank et al. May 2001 B1
6231589 Wessman et al. May 2001 B1
6234995 Peacock, III May 2001 B1
6235044 Root et al. May 2001 B1
6238416 Sideris May 2001 B1
6241727 Tu et al. Jun 2001 B1
6241738 Dereume et al. Jun 2001 B1
6241757 An et al. Jun 2001 B1
6245012 Kleshinski Jun 2001 B1
6245103 Stinson Jun 2001 B1
6251122 Tsukernik Jun 2001 B1
6254612 Hieshima Jul 2001 B1
6258026 Ravenscroft et al. Jul 2001 B1
6258124 Darois et al. Jul 2001 B1
6261318 Lee et al. Jul 2001 B1
6264654 Swartz et al. Jul 2001 B1
6264690 Von Oepen Jul 2001 B1
6267747 Samson et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6267776 O'Connell Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6270515 Linden et al. Aug 2001 B1
6273901 Whitcher et al. Aug 2001 B1
6277139 Levinson et al. Aug 2001 B1
6280413 Clark et al. Aug 2001 B1
6287335 Drasler et al. Sep 2001 B1
6311692 Vaska et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6328755 Marshall Dec 2001 B1
6331183 Suon Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6336938 Kavteladze et al. Jan 2002 B1
6340364 Kanesaka Jan 2002 B2
6342062 Suon et al. Jan 2002 B1
6342063 DeVries et al. Jan 2002 B1
6344053 Boneau Feb 2002 B1
6352552 Levinson et al. Mar 2002 B1
6355052 Neuss et al. Mar 2002 B1
6358230 Davey Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6361546 Khosravi Mar 2002 B1
6371969 Tsugita et al. Apr 2002 B1
6371971 Tsugita et al. Apr 2002 B1
6379368 Corcoran et al. Apr 2002 B1
6391044 Yadav et al. May 2002 B1
6398792 O'Connor Jun 2002 B1
6402736 Brown et al. Jun 2002 B1
6416293 Bouchard et al. Jul 2002 B1
6422397 Lynn et al. Jul 2002 B1
6428559 Johnson Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6436120 Meglin Aug 2002 B1
6436121 Blom Aug 2002 B1
6440077 Jung et al. Aug 2002 B1
6440152 Gainor et al. Aug 2002 B1
6443972 Bosma et al. Sep 2002 B1
6447530 Ostrovsky et al. Sep 2002 B1
6451257 Flamer Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6461370 Gray et al. Oct 2002 B1
6468299 Stack et al. Oct 2002 B2
6468303 Amplatz et al. Oct 2002 B1
6482222 Bruckheimer et al. Nov 2002 B1
6485497 Wensel et al. Nov 2002 B2
6485502 Don Michael et al. Nov 2002 B2
6488692 Spence et al. Dec 2002 B1
6491712 O'Connor Dec 2002 B1
6497709 Heath Dec 2002 B1
6506204 Mazzocchi Jan 2003 B2
6506205 Goldberg et al. Jan 2003 B2
6506408 Palasis Jan 2003 B1
6508777 Macoviak et al. Jan 2003 B1
6508782 Evans et al. Jan 2003 B1
6508833 Pavcnik et al. Jan 2003 B2
6517559 O'Connell Feb 2003 B1
6517573 Pollock et al. Feb 2003 B1
6527962 Nadal Mar 2003 B1
6533805 Jervis Mar 2003 B1
6534035 Reed Mar 2003 B1
6537300 Girton Mar 2003 B2
6540767 Walak et al. Apr 2003 B1
6540768 Diaz et al. Apr 2003 B1
6544167 Buckberg et al. Apr 2003 B2
6544279 Hopkins et al. Apr 2003 B1
6544280 Daniel et al. Apr 2003 B1
6547754 Evans et al. Apr 2003 B1
6551303 Van Tassel et al. Apr 2003 B1
6551344 Thill Apr 2003 B2
6562064 deBeer May 2003 B1
6562071 Jarvinen May 2003 B2
6576001 Werneth et al. Jun 2003 B2
6579308 Jansen et al. Jun 2003 B1
6582447 Patel et al. Jun 2003 B1
6585689 Macoviak et al. Jul 2003 B1
6585756 Strecker Jul 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6596011 Johnson et al. Jul 2003 B2
6596013 Yang et al. Jul 2003 B2
6599314 Mathis Jul 2003 B2
6602272 Boylan et al. Aug 2003 B2
6602281 Klein Aug 2003 B1
6605074 Zadno-Azizi et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6605110 Harrison Aug 2003 B2
6610006 Amid et al. Aug 2003 B1
6610085 Lazarus Aug 2003 B1
6613076 Cherif-Cheikh Sep 2003 B1
6616679 Khosravi et al. Sep 2003 B1
6616680 Thielen Sep 2003 B1
6616681 Hanson et al. Sep 2003 B2
6616684 Vidlund et al. Sep 2003 B1
6623448 Slater Sep 2003 B2
6623506 McGuckin, Jr. et al. Sep 2003 B2
6623507 Saleh Sep 2003 B2
6626899 Houser et al. Sep 2003 B2
6626937 Cox Sep 2003 B1
6635070 Leeflang et al. Oct 2003 B2
6638259 Palasis et al. Oct 2003 B1
6645143 Vantassel et al. Nov 2003 B2
6645152 Jung et al. Nov 2003 B1
6645202 Pless et al. Nov 2003 B1
6645225 Atkinson Nov 2003 B1
6652554 Wholey et al. Nov 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6652556 VanTassel et al. Nov 2003 B1
6656203 Roth et al. Dec 2003 B2
6656206 Corcoran et al. Dec 2003 B2
6656220 Gomez et al. Dec 2003 B1
6656221 Taylor et al. Dec 2003 B2
6660021 Palmer et al. Dec 2003 B1
6660031 Tran et al. Dec 2003 B2
6663606 Barry et al. Dec 2003 B1
6663651 Krolik et al. Dec 2003 B2
6669708 Nissenbaum et al. Dec 2003 B1
6673102 Vonesh et al. Jan 2004 B1
6676666 Vrba et al. Jan 2004 B2
6676682 Tsugita et al. Jan 2004 B1
6682505 Bates et al. Jan 2004 B2
6682554 Oepen et al. Jan 2004 B2
6685738 Chouinard et al. Feb 2004 B2
6689150 VanTassel et al. Feb 2004 B1
6692459 Teitelbaum Feb 2004 B2
6692508 Wensel et al. Feb 2004 B2
6692509 Wensel et al. Feb 2004 B2
6694983 Wolf et al. Feb 2004 B2
6695858 Dubrul et al. Feb 2004 B1
6695864 Macoviak et al. Feb 2004 B2
6699278 Fischell et al. Mar 2004 B2
6702835 Ginn Mar 2004 B2
6706065 Langberg et al. Mar 2004 B2
6709442 Miller et al. Mar 2004 B2
6712834 Yassour et al. Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6716238 Elliott Apr 2004 B2
6723133 Pajotin Apr 2004 B1
6726701 Gilson et al. Apr 2004 B2
6726703 Broome et al. Apr 2004 B2
6731982 Kroll et al. May 2004 B1
6736823 Darois et al. May 2004 B2
6736839 Cummings May 2004 B2
6736854 Vadurro et al. May 2004 B2
6740061 Oslund et al. May 2004 B1
6740094 Maitland et al. May 2004 B2
6740112 Yodfat et al. May 2004 B2
6740122 Pajotin May 2004 B1
6749629 Hong et al. Jun 2004 B1
6752825 Eskuri Jun 2004 B2
6754528 Bardy et al. Jun 2004 B2
6754531 Kroll et al. Jun 2004 B1
6755846 Yadav Jun 2004 B1
6755847 Eskuri Jun 2004 B2
6756094 Wang et al. Jun 2004 B1
6758830 Schaer et al. Jul 2004 B1
6761731 Majercak Jul 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6766196 Kroll et al. Jul 2004 B1
6776770 Trerotola Aug 2004 B1
6776784 Ginn Aug 2004 B2
6776793 Brown et al. Aug 2004 B2
6780183 Jimenez, Jr. et al. Aug 2004 B2
6783499 Schwartz Aug 2004 B2
6783538 McGuckin, Jr. et al. Aug 2004 B2
6790213 Cherok et al. Sep 2004 B2
6790218 Jayaraman Sep 2004 B2
6790230 Beyersdorf et al. Sep 2004 B2
6790231 Liddicoat et al. Sep 2004 B2
6793666 Hansen et al. Sep 2004 B2
6795731 Kroll et al. Sep 2004 B1
6797083 Peterson Sep 2004 B2
6799357 Webb et al. Oct 2004 B2
6805128 Pless et al. Oct 2004 B1
6805129 Pless et al. Oct 2004 B1
6805711 Quijano et al. Oct 2004 B2
6808537 Michelson Oct 2004 B2
6827731 Armstrong et al. Dec 2004 B2
6835378 Davis et al. Dec 2004 B2
6840950 Stanford et al. Jan 2005 B2
6843798 Kusleika et al. Jan 2005 B2
6849084 Rabkin et al. Feb 2005 B2
6866662 Fuimaono et al. Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6878162 Bales et al. Apr 2005 B2
6881218 Beyer et al. Apr 2005 B2
6887214 Levin et al. May 2005 B1
6887257 Salahieh et al. May 2005 B2
6887268 Butaric et al. May 2005 B2
6890353 Cohn et al. May 2005 B2
6895265 Silver May 2005 B2
6899727 Armstrong et al. May 2005 B2
6902572 Beulke et al. Jun 2005 B2
6905479 Bouchard et al. Jun 2005 B1
6907286 Kroll et al. Jun 2005 B1
6911037 Gainor et al. Jun 2005 B2
6913614 Marino et al. Jul 2005 B2
6913622 Gjunter Jul 2005 B2
6929633 Evans et al. Aug 2005 B2
6929660 Ainsworth et al. Aug 2005 B1
6931280 Yang Aug 2005 B1
6939361 Kleshinski Sep 2005 B1
6942635 Rosenblatt et al. Sep 2005 B2
6951570 Linder et al. Oct 2005 B2
6955688 Wilson et al. Oct 2005 B2
6962598 Linder et al. Nov 2005 B2
6966886 Appling Nov 2005 B2
6972025 WasDyke Dec 2005 B2
6974469 Broome et al. Dec 2005 B2
6976967 Dahl et al. Dec 2005 B2
6988983 Connors et al. Jan 2006 B2
6989021 Bosma et al. Jan 2006 B2
6994718 Groothuis et al. Feb 2006 B2
6997938 Wang et al. Feb 2006 B2
6997939 Linder et al. Feb 2006 B2
7001406 Eskuri et al. Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7012106 Yuan et al. Mar 2006 B2
7014765 Dannenmaier Mar 2006 B2
7052487 Cohn et al. May 2006 B2
7052500 Bashiri et al. May 2006 B2
7052511 Weldon et al. May 2006 B2
7056286 Ravenscroft et al. Jun 2006 B2
7056336 Armstrong et al. Jun 2006 B2
7060082 Goll et al. Jun 2006 B2
7063682 Whayne et al. Jun 2006 B1
7066951 Chobotov Jun 2006 B2
7083633 Morrill et al. Aug 2006 B2
7087069 Petrovic et al. Aug 2006 B2
7094249 Broome et al. Aug 2006 B1
7112219 Vidlund et al. Sep 2006 B2
7122034 Belhe et al. Oct 2006 B2
7122049 Banas et al. Oct 2006 B2
7125420 Rourke et al. Oct 2006 B2
7131966 Tamari Nov 2006 B1
7131993 Gregorich Nov 2006 B2
7137991 Fedie Nov 2006 B2
7137993 Acosta et al. Nov 2006 B2
7147649 Thomas Dec 2006 B2
7149587 Wardle et al. Dec 2006 B2
7152452 Kokish Dec 2006 B2
7163553 Limon Jan 2007 B2
7169165 Belef et al. Jan 2007 B2
7179274 Bruckheimer et al. Feb 2007 B2
7179275 McGuckin, Jr. et al. Feb 2007 B2
7179291 Rourke et al. Feb 2007 B2
7181261 Silver et al. Feb 2007 B2
7186262 Saadat Mar 2007 B2
7186264 Liddicoat et al. Mar 2007 B2
7189203 Lau et al. Mar 2007 B2
7192434 Anderson et al. Mar 2007 B2
7209783 Fellows et al. Apr 2007 B2
7214237 Don Michael et al. May 2007 B2
7220271 Clubb et al. May 2007 B2
7226464 Garner et al. Jun 2007 B2
7229462 Sutton et al. Jun 2007 B2
7229469 Witzel et al. Jun 2007 B1
7231260 Wallace et al. Jun 2007 B2
7232453 Shimon Jun 2007 B2
7241257 Ainsworth et al. Jul 2007 B1
7241310 Taylor et al. Jul 2007 B2
7250049 Roop et al. Jul 2007 B2
7252679 Fischell et al. Aug 2007 B2
7258697 Cox et al. Aug 2007 B1
7285119 Stewart et al. Oct 2007 B2
7294214 Craig Nov 2007 B2
7294311 Coville Nov 2007 B2
7303560 Chin et al. Dec 2007 B2
7306618 Demond et al. Dec 2007 B2
7306622 Jones et al. Dec 2007 B2
7309354 Mathis et al. Dec 2007 B2
7316708 Gordon et al. Jan 2008 B2
7319035 Vacanti et al. Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7323002 Johnson et al. Jan 2008 B2
7323003 Lowe Jan 2008 B2
7329269 Shapiro et al. Feb 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7331992 Randall et al. Feb 2008 B2
7338512 McGuckin, Jr. et al. Mar 2008 B2
7344553 Opolski et al. Mar 2008 B2
7344560 Gregorich et al. Mar 2008 B2
7351259 Swinford et al. Apr 2008 B2
7357812 Andreas et al. Apr 2008 B2
7359752 Bornzin et al. Apr 2008 B1
7363082 Ransbury et al. Apr 2008 B2
7364588 Mathis et al. Apr 2008 B2
7399308 Borillo et al. Jul 2008 B2
7431691 Wilk Oct 2008 B1
7445630 Lashinski et al. Nov 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7520890 Phillips Apr 2009 B2
7556644 Burpee Jul 2009 B2
7594927 Majercak et al. Sep 2009 B2
7604870 Chernyshov et al. Oct 2009 B2
7611531 Calisse Nov 2009 B2
7722661 Lenz et al. May 2010 B2
7883538 To et al. Feb 2011 B2
20010039434 Frazier Nov 2001 A1
20010044650 Simso et al. Nov 2001 A1
20020045935 Jang Apr 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020169474 Kusleika et al. Nov 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20030004567 Boyle Jan 2003 A1
20030028213 Thill et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030097172 Shalev et al. May 2003 A1
20030109887 Galdonik et al. Jun 2003 A1
20030114920 Caro et al. Jun 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030144694 Chanduszko et al. Jul 2003 A1
20030167068 Amplatz Sep 2003 A1
20030191495 Ryan et al. Oct 2003 A1
20030195555 Khairkhahan et al. Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030199923 Khairkhahan et al. Oct 2003 A1
20030204203 Khairkhahan et al. Oct 2003 A1
20030208232 Blaeser et al. Nov 2003 A1
20030225421 Peavey et al. Dec 2003 A1
20040006381 Sequin et al. Jan 2004 A1
20040039442 St. Goar et al. Feb 2004 A1
20040073242 Chanduszko Apr 2004 A1
20040088044 Brown et al. May 2004 A1
20040092973 Chanduszko et al. May 2004 A1
20040093017 Chanduszko May 2004 A1
20040102807 Kusleika et al. May 2004 A1
20040133236 Chanduszko Jul 2004 A1
20040147997 Gittings Jul 2004 A1
20040158247 Sitiso et al. Aug 2004 A1
20040158312 Chouinard et al. Aug 2004 A1
20040167609 Majercak Aug 2004 A1
20040176799 Chanduszko et al. Sep 2004 A1
20040186556 Hogendijk et al. Sep 2004 A1
20040186560 Alt Sep 2004 A1
20040204752 Ehr et al. Oct 2004 A1
20040215219 Eldridge Oct 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040249408 Murphy et al. Dec 2004 A1
20040267191 Gifford, III et al. Dec 2004 A1
20040267306 Blaeser et al. Dec 2004 A1
20040267350 Roubin Dec 2004 A1
20050015136 Lkeuchi et al. Jan 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050055080 Istephanous et al. Mar 2005 A1
20050090857 Kusleika et al. Apr 2005 A1
20050090858 Pavlovic Apr 2005 A1
20050107863 Brown May 2005 A1
20050131451 Kleshinski et al. Jun 2005 A1
20050131516 Greenhalgh Jun 2005 A1
20050192620 Cully et al. Sep 2005 A1
20050192626 Widomski et al. Sep 2005 A1
20050192654 Chanduszko et al. Sep 2005 A1
20050197186 Ohta Sep 2005 A1
20050197187 Mitsuyoshi et al. Sep 2005 A1
20050216054 Widomski et al. Sep 2005 A1
20050288764 Snow et al. Dec 2005 A1
20060015137 WasDyke Jan 2006 A1
20060020322 Leynov et al. Jan 2006 A1
20060106452 Niermann May 2006 A1
20060116751 Bayle et al. Jun 2006 A1
20060142849 Killion et al. Jun 2006 A1
20060247759 Burpee et al. Nov 2006 A1
20070055348 Pryor Mar 2007 A1
20070129786 Beach et al. Jun 2007 A1
20070185563 Zarbatany et al. Aug 2007 A1
20070198050 Ravenscroft et al. Aug 2007 A1
20070219618 Cully et al. Sep 2007 A1
20070232981 Ravenscroft et al. Oct 2007 A1
20070255387 Kramer et al. Nov 2007 A1
20080103584 Su et al. May 2008 A1
20080109068 Fischell et al. May 2008 A1
20080125849 Burpee et al. May 2008 A1
20080208319 Rabkin et al. Aug 2008 A1
20080215129 Venturelli et al. Sep 2008 A1
20080294240 Casey Nov 2008 A1
20080306581 Berglund et al. Dec 2008 A1
20090024205 Hebert et al. Jan 2009 A1
20090036976 Beach et al. Feb 2009 A1
20090099592 Buiser et al. Apr 2009 A1
20090118810 Klein et al. May 2009 A1
20090163989 Contiliano et al. Jun 2009 A1
20090182407 Leanna et al. Jul 2009 A1
20090210049 Thielen et al. Aug 2009 A1
20090264978 Dieck et al. Oct 2009 A1
20100004730 Benjamin et al. Jan 2010 A1
20100023106 Meyer et al. Jan 2010 A1
20100057187 Caldarise et al. Mar 2010 A1
20100076545 Kleshinski et al. Mar 2010 A1
20100137973 Sutermeister Jun 2010 A1
20100222772 Kleshinski et al. Sep 2010 A1
20100294287 Raju et al. Nov 2010 A1
20110251671 Heraty et al. Oct 2011 A1
20110301685 Kao Dec 2011 A1
20110307049 Kao Dec 2011 A1
20120078341 Kao Mar 2012 A1
20120078344 Kao Mar 2012 A1
Foreign Referenced Citations (36)
Number Date Country
0362113 Apr 1990 EP
0221570 Jan 1991 EP
0335341 Mar 1992 EP
0541063 May 1993 EP
0621016 Oct 1993 EP
0657147 Jun 1995 EP
0701800 Mar 1996 EP
0962194 Dec 1999 EP
1050265 Nov 2000 EP
1304091 Apr 2003 EP
1917931 May 2008 EP
06189971 Jul 1994 JP
06343703 Dec 1994 JP
07265339 Oct 1995 JP
08089585 Apr 1996 JP
08215200 Aug 1996 JP
08257031 Oct 1996 JP
08299456 Nov 1996 JP
2000126304 May 2000 JP
2002119516 Apr 2002 JP
2002525183 Aug 2002 JP
2002355248 Dec 2002 JP
2003521308 Jul 2003 JP
2003521988 Jul 2003 JP
WO9713463 Apr 1997 WO
WO 9838945 Sep 1998 WO
WO 9944540 Sep 1999 WO
WO 0016718 Mar 2000 WO
WO 0028922 May 2000 WO
WO 0057813 Oct 2000 WO
WO 03051425 Jun 2003 WO
WO03101312 Dec 2003 WO
WO2007040249 Apr 2007 WO
WO 2007092276 Aug 2007 WO
WO2008060345 May 2008 WO
WO2011053737 May 2011 WO
Non-Patent Literature Citations (7)
Entry
Duerig et al.; An overview of superelastic stent design; Min Invas Ther & Allied Technol; vol. 9(3/4); pp. 235-246; 2000.
Malvé et al.; FSI analysis of the coughing mechanism in a human trachea; Annals of Biomedical Engineering; vol. 38; No. 4; pp. 1556-1565; 2010.
Bonsignore et al.; U.S. Appl. No. 13/100,132 entitled “Alternating circumferential bridge stent design and methods for use therof,” filed May 3, 2011.
Boston Scientific Corp.; Ultraflex Tracheobronchial Stent System (prod. info.); www.bostonscientific.com/templatedata/imports/collateral/PulmonaryEndoscopy/prospec_ultrixtb_01_us.pdf; 2 pgs.; 2007 (pub. year sufficiently earlier than eff. US filing date & any foreign priority date).
Raju et al.; U.S. Appl. No. 11/944,094 entitled “Venous Stent,” filed Nov. 21, 2007.
Raju et al.; U.S. Appl. No. 12/903,056 entitled “Venous Stent,” filed Oct. 12, 2010.
Raju et al.; U.S. Appl. No. 12/603,970 entitled “Venous Stent,” filed Oct. 22, 2009.
Related Publications (1)
Number Date Country
20110106237 A1 May 2011 US
Provisional Applications (3)
Number Date Country
61391462 Oct 2010 US
61290836 Dec 2009 US
61258145 Nov 2009 US